These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21406545)

  • 1. Aggregated serum free light chains may prevent adequate removal by high cut-off haemodialysis.
    Harding S; Provot F; Beuscart JB; Cook M; Bradwell AR; Stringer S; White D; Cockwell P; Hutchison CA
    Nephrol Dial Transplant; 2011 Apr; 26(4):1438. PubMed ID: 21406545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: preliminary quantitative study.
    Granger Vallée A; Chenine L; Leray-Moragues H; Patrier L; Cognot C; Cartron G; Cristol JP; Canaud B
    Nephrol Dial Transplant; 2011 Nov; 26(11):3627-33. PubMed ID: 21508098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
    Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
    BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
    Hutchison CA; Heyne N; Airia P; Schindler R; Zickler D; Cook M; Cockwell P; Grima D
    Nephrol Dial Transplant; 2012 Oct; 27(10):3823-8. PubMed ID: 22273664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.
    Borrego-Hinojosa J; Pérez-del Barrio MP; Biechy-Baldan Mdel M; Merino-García E; Sánchez-Perales MC; García-Cortés MJ; Ocaña-Pérez E; Gutiérrez-Rivas P; Liébana-Cañada A
    Nefrologia; 2013; 33(4):515-23. PubMed ID: 23897183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.
    Hutchison CA; Cockwell P; Reid S; Chandler K; Mead GP; Harrison J; Hattersley J; Evans ND; Chappell MJ; Cook M; Goehl H; Storr M; Bradwell AR
    J Am Soc Nephrol; 2007 Mar; 18(3):886-95. PubMed ID: 17229909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012.
    Tan J; Lam-Po-Tang M; Hutchison CA; de Zoysa JR
    Nephrology (Carlton); 2014 Jul; 19(7):432-5. PubMed ID: 24931113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cast nephropathy with acute renal failure treated with high cut-off haemodialysis in a patient with multiple myeloma.
    Shum HP; Chan KC; Chow CC; Kho BC; Yan WW
    Hong Kong Med J; 2010 Dec; 16(6):489-92. PubMed ID: 21135429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management options for cast nephropathy in multiple myeloma.
    Cockwell P; Hutchison CA
    Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):550-5. PubMed ID: 20827195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma.
    Martín-Reyes G; Toledo-Rojas R; Torres-de Rueda Á; Sola-Moyano E; Blanca-Martos L; Fuentes-Sánchez L; Martínez-Esteban MD; Díez-de los Ríos MJ; Bailén-García A; González-Molina M; García-González I
    Nefrologia; 2012; 32(1):35-43. PubMed ID: 22294003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelled cost-effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney.
    Grima DT; Airia P; Attard C; Hutchison CA
    Curr Med Res Opin; 2011 Feb; 27(2):383-91. PubMed ID: 21175375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma].
    Shimizu K; Itoh J; Sugiura I; Tsushita K; Kosugi H; Nagura E
    Rinsho Ketsueki; 2006 Apr; 47(4):303-9. PubMed ID: 16715965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
    Hasegawa M; Kondo F; Yamamoto K; Murakami K; Tomita M; Nabeshima K; Nakai S; Kato M; Ohashi A; Arai J; Hiki Y; Ishii J; Emi N; Sugiyama S; Yuzawa Y
    Ther Apher Dial; 2010 Oct; 14(5):451-6. PubMed ID: 21175542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dialysis on serum/plasma levels of free immunoglobulin light chains in end-stage renal disease patients.
    Cohen G; Rudnicki M; Schmaldienst S; Hörl WH
    Nephrol Dial Transplant; 2002 May; 17(5):879-83. PubMed ID: 11981077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.
    Cockwell P; Cook M
    Adv Chronic Kidney Dis; 2012 Sep; 19(5):324-32. PubMed ID: 22920643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care.
    Hutchison CA; Harding S; Mead G; Goehl H; Storr M; Bradwell A; Cockwell P
    Artif Organs; 2008 Dec; 32(12):910-7. PubMed ID: 19133018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of free light chain removal by four blood purification methods.
    Kanayama K; Ohashi A; Hasegawa M; Kondo F; Yamamoto Y; Sasaki M; Hayashi H; Kato M; Hattori R; Yamashita H; Arai J; Ishii J; Emi N; Yuzawa Y
    Ther Apher Dial; 2011 Aug; 15(4):394-9. PubMed ID: 21884475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum free light chains for monitoring multiple myeloma.
    Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
    Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High cut-off dialysis membranes: current uses and future potential.
    Gondouin B; Hutchison CA
    Adv Chronic Kidney Dis; 2011 May; 18(3):180-7. PubMed ID: 21531324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
    Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
    Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.